Neridronate

DRUG3 trials

Sponsors

Ente Ospedaliero Ospedali Galliera, ASST Gaetano Pini-CTO, Ambros Therapeutics, Inc.

Conditions

Complex Regional Pain Syndrome Type IOsteoarthritis, KneeOsteoporosisThalassemia IntermediaThalassemia Major

Phase 2

Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI

CompletedNCT01140321

Ente Ospedaliero Ospedali GallieraOsteoporosis, Thalassemia Intermedia, Thalassemia Major

Start: 2004-01-31End: 2010-05-31Updated: 2020-02-05

Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.

ASST Gaetano Pini-CTOOsteoarthritis, Knee

Start: 2013-03-31End: 2013-09-30Target: 60Updated: 2013-03-14

Phase 3

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

RecruitingNCT07210515

Ambros Therapeutics, Inc.Complex Regional Pain Syndrome Type I

Start: 2026-04-14End: 2028-01-01Target: 270Updated: 2026-09-10

Related Papers

Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study

Lara D. Veeken2015-05-2061 citations

Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.

2012-05-1032 citations